Dupixent (dupilumab) approved in China for adults with moderate to severe atopic dermatitis

Sanofi

19 June 2020 - Dupixent included in China’s list of overseas approved drugs that meet urgent clinical need.

The National Medical Products Administration in China has approved Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. 

The National Medical Products Administration has identified Dupixent as an overseas medicine considered urgently needed in clinical practice, leading to an expedited review and approval process.

Read Sanofi press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , China